These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 11322207)

  • 1. Efficacy of 5 MU of interferon in combination with ribavirin for naïve patients with chronic hepatitis C virus: a randomized controlled trial.
    Mangi A; Villani MR; Minerva N; Leandro G; Bacca D; Cela M; Carretta V; Attino V; Ventrella F; Giangaspero A; Andriulli A
    J Hepatol; 2001 Mar; 34(3):441-6. PubMed ID: 11322207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pattern of response to interferon alpha (alpha-IFN) predicts sustained response to a 6-month alpha-IFN and ribavirin retreatment for chronic hepatitis C. TVVH Study Group.
    Cavalletto L; Chemello L; Donada C; Casarin P; Belussi F; Bernardinello E; Marino F; Pontisso P; Gatta A; Alberti A
    J Hepatol; 2000 Jul; 33(1):128-34. PubMed ID: 10905596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon.
    Di Bisceglie AM; Thompson J; Smith-Wilkaitis N; Brunt EM; Bacon BR
    Hepatology; 2001 Mar; 33(3):704-7. PubMed ID: 11230751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of interferon alpha-2b induction therapy before retreatment for chronic hepatitis C.
    Carr C; Hollinger FB; Yoffe B; Wakil A; Phillips J; Bzowej N; Leung J; Mirro K; Poordad F; Moore DH; Gish RG
    Liver Int; 2007 Oct; 27(8):1111-8. PubMed ID: 17845540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C.
    Mangia A; Minerva N; Annese M; Leandro G; Villani MR; Santoro R; Carretta V; Bacca D; Giangaspero A; Bisceglia M; Ventrella F; Dell'Erba G; Andriulli A
    Hepatology; 2001 Apr; 33(4):989-93. PubMed ID: 11283865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy.
    McHutchison JG; Shad JA; Gordon SC; Morgan TR; Ling MH; Garaud JJ; Albrecht JK; Dienstag JL
    J Viral Hepat; 2001 Nov; 8(6):414-20. PubMed ID: 11703572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial to assess the efficacy of interferon-alpha daily in combination with ribavirin in the treatment of naïve patients with chronic hepatitis C.
    Tassopoulos NC; Ketikoglou I; Tsantoulas D; Raptopoulou M; Hatzis G; Vafiadis I; Sidiropoulos L; Kanatakis S; Anagnostopoulos G; Sypsa V; Hatzakis A;
    J Viral Hepat; 2003 Sep; 10(5):383-9. PubMed ID: 12969190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.
    Liu CH; Huang CF; Liu CJ; Dai CY; Liang CC; Huang JF; Hung PH; Tsai HB; Tsai MK; Chen SI; Lin JW; Yang SS; Su TH; Yang HC; Chen PJ; Chen DS; Chuang WL; Yu ML; Kao JH
    Ann Intern Med; 2013 Dec; 159(11):729-38. PubMed ID: 24297189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time course of serum hepatitis C virus-RNA during chronic hepatitis C treatment accurately predicts the type of response.
    Calleja JL; Albillos A; Rossi I; Moreno R; Domper F; Martínez JL; Escartín P
    Aliment Pharmacol Ther; 2001 Feb; 15(2):241-9. PubMed ID: 11148444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients.
    Taliani G; Gemignani G; Ferrari C; Aceti A; Bartolozzi D; Blanc PL; Capanni M; Esperti F; Forte P; Guadagnino V; Mari T; Marino N; Milani S; Pasquazzi C; Rosina F; Tacconi D; Toti M; Zignego AL; Messerini L; Stroffolini T;
    Gastroenterology; 2006 Apr; 130(4):1098-106. PubMed ID: 16618404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis.
    Mangia A; Santoro R; Piattelli M; Leandro G; Minerva N; Annese M; Bacca D; Spirito F; Carretta V; Ventrella F; Cela M; Andriulli A
    J Hepatol; 2002 Jul; 37(1):109-16. PubMed ID: 12076869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone.
    Saracco G; Ciancio A; Olivero A; Smedile A; Roffi L; Croce G; Colletta C; Cariti G; Andreoni M; Biglino A; Calleri G; Maggi G; Tappero GF; Orsi PG; Terreni N; Macor A; Di Napoli A; Rinaldi E; Ciccone G; Rizzetto M
    Hepatology; 2001 Jul; 34(1):133-8. PubMed ID: 11431744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C.
    Teuber G; Pascu M; Berg T; Lafrenz M; Pausch J; Kullmann F; Ramadori G; Arnold R; Weidenbach H; Musch E; Junge U; Wiedmann KH; Herrmann E; Zankel M; Zeuzem S
    J Hepatol; 2003 Oct; 39(4):606-13. PubMed ID: 12971972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial of prolonged high dose of interferon plus ribavirin for hepatitis C patients nonresponders to interferon alone.
    Fattovich G; Zagni I; Ribero ML; Castagnetti E; Minola E; Lomonaco L; Scattolini C; Fabris P; Boccia S; Giusti M; Abbati G; Felder M; Rovere P; Redaelli A; Tonon A; Tomba A; Montanari R; Paternoster C; Distasi M; Fornaciari G; Tositti G; Rizzo C; Suppressa S; Pantalena M; Noventa F; Tagger A
    J Viral Hepat; 2004 Nov; 11(6):543-51. PubMed ID: 15500555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months.
    Di Marco V; Almasio P; Vaccaro A; Ferraro D; Parisi P; Cataldo MG; Di Stefano R; Craxì A
    J Hepatol; 2000 Sep; 33(3):456-62. PubMed ID: 11020002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon alfacon-1 and ribavirin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis C.
    Sjogren MH; Sjogren R; Holtzmuller K; Winston B; Butterfield B; Drake S; Watts A; Howard R; Smith M
    Dig Dis Sci; 2005 Apr; 50(4):727-32. PubMed ID: 15844709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers.
    Schalm SW; Hansen BE; Chemello L; Bellobuono A; Brouwer JT; Weiland O; Cavalletto L; Schvarcz R; Ideo G; Alberti A
    J Hepatol; 1997 May; 26(5):961-6. PubMed ID: 9186825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
    Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
    J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load.
    Tsubota A; Arase Y; Suzuki F; Suzuki Y; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kumada H
    J Gastroenterol; 2004; 39(2):155-61. PubMed ID: 15069622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.